X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Dr. Reddys - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs DR. REDDYS LAB - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH DR. REDDYS LAB STERLING BIOTECH/
DR. REDDYS LAB
 
P/E (TTM) x -1.6 29.9 - View Chart
P/BV x 0.1 2.9 2.2% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 STERLING BIOTECH   DR. REDDYS LAB
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
DR. REDDYS LAB
Mar-17
STERLING BIOTECH/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs113,397 0.3%   
Low Rs32,560 0.1%   
Sales per share (Unadj.) Rs26.8856.5 3.1%  
Earnings per share (Unadj.) Rs-15.078.0 -19.2%  
Cash flow per share (Unadj.) Rs-5.5139.9 -3.9%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.7 0.0%  
Book value per share (Unadj.) Rs54.9739.8 7.4%  
Shares outstanding (eoy) m267.87165.74 161.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x0.33.5 7.5%   
Avg P/E ratio x-0.538.2 -1.2%  
P/CF ratio (eoy) x-1.321.3 -6.0%  
Price / Book Value ratio x0.14.0 3.1%  
Dividend payout %025.7 0.0%   
Avg Mkt Cap Rs m1,862493,632 0.4%   
No. of employees `0001.422.7 6.0%   
Total wages/salary Rs m54731,068 1.8%   
Avg. sales/employee Rs Th5,303.36,259.0 84.7%   
Avg. wages/employee Rs Th403.81,369.8 29.5%   
Avg. net profit/employee Rs Th-2,959.0569.7 -519.4%   
INCOME DATA
Net Sales Rs m7,181141,961 5.1%  
Other income Rs m431,715 2.5%   
Total revenues Rs m7,223143,676 5.0%   
Gross profit Rs m94724,722 3.8%  
Depreciation Rs m2,54310,266 24.8%   
Interest Rs m4,377634 690.4%   
Profit before tax Rs m-5,93115,537 -38.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0349 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9242,965 -64.9%   
Profit after tax Rs m-4,00712,921 -31.0%  
Gross profit margin %13.217.4 75.7%  
Effective tax rate %32.419.1 170.0%   
Net profit margin %-55.89.1 -613.0%  
BALANCE SHEET DATA
Current assets Rs m14,33596,837 14.8%   
Current liabilities Rs m49,80984,199 59.2%   
Net working cap to sales %-494.08.9 -5,549.3%  
Current ratio x0.31.2 25.0%  
Inventory Days Days40373 549.9%  
Debtors Days Days17198 174.7%  
Net fixed assets Rs m55,432102,552 54.1%   
Share capital Rs m268829 32.3%   
"Free" reserves Rs m13,935121,792 11.4%   
Net worth Rs m14,701122,621 12.0%   
Long term debt Rs m9,4785,449 173.9%   
Total assets Rs m73,988218,165 33.9%  
Interest coverage x-0.425.5 -1.4%   
Debt to equity ratio x0.60 1,450.8%  
Sales to assets ratio x0.10.7 14.9%   
Return on assets %0.56.2 8.1%  
Return on equity %-27.310.5 -258.6%  
Return on capital %-6.412.9 -49.8%  
Exports to sales %25.954.6 47.4%   
Imports to sales %0.29.4 1.8%   
Exports (fob) Rs m1,86077,520 2.4%   
Imports (cif) Rs m1213,274 0.1%   
Fx inflow Rs m1,86081,670 2.3%   
Fx outflow Rs m2526,355 0.1%   
Net fx Rs m1,83555,315 3.3%   
CASH FLOW
From Operations Rs m1,71921,444 8.0%  
From Investments Rs m-3,148-18,404 17.1%  
From Financial Activity Rs m1,426-3,692 -38.6%  
Net Cashflow Rs m-3-1,144 0.3%  

Share Holding

Indian Promoters % 33.9 25.5 132.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 5.4 -  
FIIs % 9.9 35.3 28.0%  
ADR/GDR % 16.9 18.5 91.4%  
Free float % 39.3 15.3 256.9%  
Shareholders   21,482 75,885 28.3%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   SHASUN PHARMA  CIPLA  ASTRAZENECA PHARMA  SUVEN LIFE  IPCA LABS  

Compare STERLING BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Galaxy Surfactants Ltd. (IPO)

Jan 27, 2018

Should you subscribe to the IPO of Galaxy Surfactants Ltd?

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Feb 23, 2018 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS